Discover
WGS
GeneDx Holdings Corp.
67.33
2 x 50.76
2 x 88.61
bid
ask
-
0.40
0.59%
2 @ 04:00 PM
67.33 +0.00 (0.00%)
| Ytd | -48.23% | |
| 1y | -46.90% |
67.22
day range
69.73
34.51
52 week range
167.51
| Open | 68.45 | Prev Close | 67.73 | Low | 67.22 | High | 69.73 | Mkt Cap | 2.01B |
| Vol | 405.12K | Avg Vol | 730.21K | EPS | -3.63 | P/E | N/A | Forward P/E | 56.18 |
| Beta | 1.97 | Short Ratio | 11.93 | Inst. Own | 107.61% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-27 | 50-d Avg | 82.04 | 200-d Avg | 77.03 | 1yr Est | 93.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-10-27 | 2026-09 | 0.07 | N/A | N/A | N/A |
| 2026-08-03 | 2026-06 | -0.19 | 0.01 | 0.2 | 105.32% |
| 2026-05-04 | 2026-03 | -0.06 | -0.28 | -0.22 | -366.67% |
| 2026-02-23 | 2025-12 | 0.11 | 0.14 | 0.03 | 27.27% |
| 2025-10-28 | 2025-09 | 0.28 | 0.49 | 0.21 | 75.00% |
| 2025-07-29 | 2025-06 | 0.1 | 0.5 | 0.4 | 400.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-10-01 | Guggenheim | Upgrade | Buy | Buy |
| 2026-08-04 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-08-04 | BTIG | Upgrade | Buy | Buy |
| 2026-06-29 | Guggenheim | Upgrade | Buy | Buy |
| 2026-06-23 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2026-05-05 | Canaccord Genuity | Upgrade | Buy | Buy |
Profile
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-04 | CASDIN CAPITAL, LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2026-06-17 | CASDIN ELI | Director and Beneficial Owner of more than 10% of a Class of Security | 4.08M | Conversion of Exercise of derivative security |
| 2026-09-08 | FEELEY KEVIN | Chief Financial Officer | 41.48K | Sale |
| 2024-11-17 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | Beneficial Owner of more than 10% of a Class of Security | 2.72M | Sale |
| 2026-06-17 | LEPROUST EMILY M | Director | 24.85K | Conversion of Exercise of derivative security |
| 2026-06-17 | MEISTER KEITH A | Director and Beneficial Owner of more than 10% of a Class of Security | 5.14M | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Corvex Management LP | 4.78M | 322.15M | 16.04% |
| 2026-06-29 | Casdin Capital, LLC | 3.71M | 249.60M | 12.43% |
| 2026-06-29 | Blackrock Inc. | 1.71M | 114.88M | 5.72% |
| 2026-06-29 | Goldman Sachs Group Inc | 1.67M | 112.40M | 5.60% |
| 2026-06-29 | ARK Investment Management, LLC | 1.61M | 108.41M | 5.40% |
| 2026-06-29 | William Blair Investment Management, LLC | 1.40M | 94.31M | 4.70% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-08-30 | ARK ETF Trust-ARK Innovation ETF | 942.44K | 63.45M | 3.16% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 607.77K | 40.92M | 2.04% |
| 2026-08-30 | ARK ETF Trust-ARK Genomic Revolution ETF | 529.63K | 35.66M | 1.78% |
| 2026-08-30 | iShares Trust-iShares Russell 2000 ETF | 515.45K | 34.71M | 1.73% |
| 2026-06-29 | MUTUAL FUND SERIES TRUST-Eventide Gilead Fund | 266.04K | 17.91M | 0.89% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 249.89K | 16.83M | 0.84% |
Split
| Split | Date |
|---|---|
| 1 : 33 | 2023-05-04 |